MX2012004089A - Inhibidores de hsp90. - Google Patents

Inhibidores de hsp90.

Info

Publication number
MX2012004089A
MX2012004089A MX2012004089A MX2012004089A MX2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A MX 2012004089 A MX2012004089 A MX 2012004089A
Authority
MX
Mexico
Prior art keywords
sub
purine derivatives
derivatives useful
hsp90 inhibitors
hsp90
Prior art date
Application number
MX2012004089A
Other languages
English (en)
Other versions
MX340714B (es
Inventor
Gabriela Chiosis
Tony Taldone
Weilin Sun
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of MX2012004089A publication Critical patent/MX2012004089A/es
Publication of MX340714B publication Critical patent/MX340714B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente solicitud proporciona los derivados de purina sustituidos y los compuestos relacionados de las fórmulas mostradas. Estos compuestos son útiles como inhibidores de HSP90, y por lo tanto, en el tratamiento de las enfermedades relacionadas. (Fórmulas) Z1-Z3, Xa-XC, X2, X4, Y y R son según lo definido en la especificación.
MX2012004089A 2009-10-07 2010-10-07 Inhibidores de hsp90. MX340714B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24934909P 2009-10-07 2009-10-07
PCT/US2010/051872 WO2011044394A1 (en) 2009-10-07 2010-10-07 Purine derivatives useful as hsp90 inhibitors

Publications (2)

Publication Number Publication Date
MX2012004089A true MX2012004089A (es) 2012-08-23
MX340714B MX340714B (es) 2016-07-22

Family

ID=43857159

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004089A MX340714B (es) 2009-10-07 2010-10-07 Inhibidores de hsp90.

Country Status (16)

Country Link
US (2) US9328114B2 (es)
EP (2) EP3091019B1 (es)
JP (3) JP5941407B2 (es)
KR (2) KR101906568B1 (es)
CN (3) CN102639534A (es)
AU (1) AU2010303343B2 (es)
BR (1) BR112012008019A2 (es)
CA (1) CA2776308C (es)
DK (1) DK2486039T3 (es)
EA (1) EA029272B1 (es)
ES (2) ES2733131T3 (es)
LT (1) LT2486039T (es)
MX (1) MX340714B (es)
NZ (2) NZ599138A (es)
PT (1) PT2486039T (es)
WO (1) WO2011044394A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
CA2656202C (en) 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
BR112012008019A2 (pt) 2009-10-07 2016-03-01 Sloan Kettering Inst Cancer derivados de purina úteis como inibidores de hsp90
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
CA2841173C (en) 2011-07-08 2022-06-21 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用
CN111285813A (zh) 2013-08-23 2020-06-16 润新生物公司 化学实体、组合物和方法
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
AU2015317632B2 (en) 2014-09-17 2022-01-13 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
TW201722422A (zh) 2015-10-05 2017-07-01 美國紀念斯隆-凱特琳癌症中心 用於治療癌症之合理組合療法
EP4006035B1 (en) * 2016-08-15 2023-11-22 Neupharma, Inc. Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer
JP2020517732A (ja) * 2017-04-24 2020-06-18 サムス セラピューティクス, インコーポレーテッドSamus Therapeutics, Inc. Ｈｓｐ９０阻害剤の経口製剤及び関連する方法
AU2018290288A1 (en) * 2017-06-23 2020-01-16 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841549D1 (de) 1997-05-14 2010-04-22 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
JP2005519848A (ja) 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
EP1440072A4 (en) * 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
NL1019258C2 (nl) * 2001-10-30 2003-05-02 Iku Holding Montfoort Bv Bevestigingsconstructie, in het bijzonder voor een buitenspiegel van een motorvoertuig.
US7553979B2 (en) 2001-11-09 2009-06-30 Conforma Therapeutics Corporation HSP90-inhibiting zearalanol compounds and methods of producing and using same
MXPA04008312A (es) 2002-02-28 2004-11-26 Astrazeneca Ab Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos.
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
CN101906106A (zh) 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007014361A2 (en) 2005-07-27 2007-02-01 Qualcomm Incorporated System and method for a forward link only protocol suite
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
WO2007143630A2 (en) 2006-06-02 2007-12-13 Nexgenix Pharmaceuticals Treatment of neurofibromatosis with hsp90 inhibitors
CA2656202C (en) * 2006-06-30 2018-01-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
US20080053862A1 (en) 2006-06-30 2008-03-06 Sanford, L.P. Interlocking Nestable Article Holder
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
AU2008229216B2 (en) * 2007-03-20 2013-03-21 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
WO2008115262A2 (en) 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
WO2009007399A1 (en) * 2007-07-12 2009-01-15 Crystax Pharmaceuticals, S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
JP2011503206A (ja) * 2007-11-14 2011-01-27 ミレクシス， インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
BR112012008019A2 (pt) 2009-10-07 2016-03-01 Sloan Kettering Inst Cancer derivados de purina úteis como inibidores de hsp90
MX360390B (es) 2011-04-05 2018-10-31 Sloan Kettering Inst Cancer Res Inhibidores de la proteina 90 de choque termico (hsp90).
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
JP6539275B2 (ja) 2013-08-16 2019-07-03 メモリアル スローン ケタリング キャンサー センター 選択的ｇｒｐ９４阻害剤およびその使用

Also Published As

Publication number Publication date
JP5941407B2 (ja) 2016-06-29
JP6326088B2 (ja) 2018-05-16
CN105924443A (zh) 2016-09-07
EP2486039B1 (en) 2016-06-01
EP2486039A4 (en) 2012-08-15
WO2011044394A1 (en) 2011-04-14
CN106083855A (zh) 2016-11-09
JP2016145262A (ja) 2016-08-12
EP3091019B1 (en) 2019-04-03
EA029272B1 (ru) 2018-03-30
ES2733131T3 (es) 2019-11-27
CN106083855B (zh) 2020-04-10
CA2776308C (en) 2020-01-28
US20120208806A1 (en) 2012-08-16
KR20180112117A (ko) 2018-10-11
AU2010303343B2 (en) 2015-11-19
KR102129420B1 (ko) 2020-07-03
MX340714B (es) 2016-07-22
US10172863B2 (en) 2019-01-08
KR101906568B1 (ko) 2018-10-10
BR112012008019A2 (pt) 2016-03-01
KR20120083898A (ko) 2012-07-26
NZ625593A (en) 2016-03-31
JP2013507381A (ja) 2013-03-04
EP2486039A1 (en) 2012-08-15
DK2486039T3 (en) 2016-09-12
EA201270535A1 (ru) 2012-09-28
CN102639534A (zh) 2012-08-15
JP2018104451A (ja) 2018-07-05
NZ599138A (en) 2014-06-27
LT2486039T (lt) 2016-10-10
EP3091019A3 (en) 2017-01-18
PT2486039T (pt) 2016-09-06
US20160310497A1 (en) 2016-10-27
US9328114B2 (en) 2016-05-03
ES2589403T3 (es) 2016-11-14
JP6804483B2 (ja) 2020-12-23
CA2776308A1 (en) 2011-04-14
EP3091019A2 (en) 2016-11-09
AU2010303343A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
MX2012004089A (es) Inhibidores de hsp90.
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MX2012008049A (es) Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
MX2009010595A (es) Derivados de pirrolopirimidina.
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
TW200833675A (en) Nicotinamide derivatives
TN2010000167A1 (en) Organic compounds
MX2007013624A (es) Inhibidores de proteina cinasa.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
IL192253A0 (en) Substituted cyclohexylmethyl derivatives
WO2008152014A3 (en) 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
TW200630374A (en) Thiazolyldihydroindazoles
MX2012013274A (es) Novedosos derivados de la pirimidina.
TW200745066A (en) Novel PTP1B inhibitors
TN2010000038A1 (en) Organic compounds
IN2012DN03182A (es)
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
TW200639156A (en) New compounds
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY152030A (en) Novel herbicides

Legal Events

Date Code Title Description
FG Grant or registration